AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barchiesi, F.
Right arrow Articles by Scalise, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barchiesi, F.
Right arrow Articles by Scalise, G.

 Previous Article

Antimicrobial Agents and Chemotherapy, January 2000, p. 226-229, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens

Francesco Barchiesi,1,* Daniela Arzeni,1 Annette W. Fothergill,2 Luigi Falconi Di Francesco,1 Francesca Caselli,1 Michael G. Rinaldi,2,3 and Giorgio Scalise1

Istituto di Malattie Infettive e Medicina Pubblica, Università degli Studi di Ancona, Ancona, Italy1; Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center, San Antonio, Texas 72284-77502; Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas 78284-51003

Received 7 June 1999/Returned for modification 16 September 1999/Accepted 25 October 1999

A broth microdilution method performed in accordance with the National Committee for Clinical Laboratory Standards guidelines was used to compare the in vitro activity of the new antifungal triazole SCH 56592 (SCH) to that of fluconazole (FLC), itraconazole (ITC), and ketoconazole (KETO) against 257 clinical yeast isolates. They included 220 isolates belonging to 12 different species of Candida, 15 isolates each of Cryptococcus neoformans and Saccharomyces cerevisiae, and seven isolates of Rhodotorula rubra. The MICs of SCH at which 50% (MIC50) and 90% (MIC90) of the isolates were inhibited were 0.06 and 2.0 µg/ml, respectively. In general, SCH was considerably more active than FLC (MIC50 and MIC90 of 1.0 and 64 µg/ml, respectively) and slightly more active than either ITC (MIC50 and MIC90 of 0.25 and 2.0 µg/ml, respectively) and KETO (MIC50 and MIC90 of 0.125 and 4.0 µg/ml, respectively). Our in vitro data suggest that SCH has significant potential for clinical development.

* Corresponding author. Mailing address: Istituto di Malattie Infettive e Medicina Pubblica, Università degli Studi di Ancona, Ospedale Umberto I°, Largo Cappelli 1, 60121, Ancona, Italy. Phone: 39.71.5963467. Fax: 39.71.5963468. E-mail: cmalinf{at}popcsi.unian.it.

Antimicrobial Agents and Chemotherapy, January 2000, p. 226-229, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.